GlaxoSmithKline announced an investment of $30 billion in the US pharmaceutical market, coinciding with Trump's visit to the UK.

GlaxoSmithKline stated that the company's investment will include $1.2 billion for advanced manufacturing, artificial intelligence, and advanced digital technologies. The investment commitment was made during the three-day state visit of US President Trump to the UK. Under pressure from the Trump administration to boost American manufacturing and lower domestic drug prices, large pharmaceutical companies are rushing to invest in the United States.